Loading stock data…
$1.62+0.00 (+0.12%)
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology.
Lipocine Inc. in the Healthcare sector is trading at $1.62 with a market capitalization of $18M. Wall Street consensus targets $5.00 (2 analysts), implying a +208.3% move over the next 12 months. The stock is currently near its 52-week low of $1.59, remaining 62.4% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 27 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $190,099↑ | $119,397↓ | $1.15M↑ | $114,574↓ | $622,849 |
| Gross Profit | -$1.85M | — | — | — | -$1.51M |
| Operating Income | -$2.84M↑ | -$3.85M↓ | -$2.52M↑ | -$3.36M↓ | -$2.40M |
| Net Income | -$2.62M↑ | -$3.67M↓ | -$2.37M↑ | -$3.19M↓ | -$2.21M |
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprisi...